11. The polypeptide construct of claim 1, wherein the antibody comprises a human IgG1 heavy constant domain.

12. The polypeptide construct of claim 1, wherein the antibody comprises a human IgG4 heavy constant domain.

13. The polypeptide construct of claim 1, wherein the human IgG4 heavy constant domain comprises a proline at position 228.

14. The polypeptide construct of claim 12, wherein the attenuated IFN alpha has the amino acid sequence of SEQ ID NO:44.

15. The polypeptide construct of claim 13, wherein the attenuated IFN alpha has the amino acid sequence of SEQ ID NO:44.

16. A composition, comprising the polypeptide construct of claim 1 and a pharmaceutically acceptable carrier.

17. A composition, comprising the polypeptide construct of claim 14 and a pharmaceutically acceptable carrier.

18. A composition, comprising the polypeptide construct of claim 15 and a pharmaceutically acceptable carrier.